Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 17/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 17/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 17/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520304 | 1.00 | SMARCA2 (0.50) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL23037244 | 0.88 | PBRM1 (0.54) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL30520235 | 0.87 | SMARCA2 (0.50) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL25347731 | 0.87 | SMARCA2 (0.50) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL31548738 | 0.86 | SMARCA2 (0.65) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL25348666 | 0.85 | SMARCA2 (0.56) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL30520311 | 0.85 | SMARCA2 (0.56) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| Hydrochloric Acid SCHEMBL25348521 | 0.85 | PBRM1 (0.55) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| Hydrochloric Acid SCHEMBL30520261 | 0.85 | PBRM1 (0.55) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL25346314 | 0.82 | SMARCA2 (0.50) | SMARCA2SMARCA4PBRM1NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| CN-118871440-A | 3-Substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degrading agents | 奥瑞基尼肿瘤有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023152666-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | SMARCC1, SMARCC2, SMARCA4 | SMARCA2 4/4885SMARCA4 3/4885PBRM1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.